Sage wins OK for depression drug Zulresso. Up next? Major marketing challenges

Sage Therapeutics has the first-ever approval for a prescription drug for postpartum depression, thanks to the FDA’s Tuesday nod for Zulresso. But it also has a number of big challenges ahead. Regulators greenlighted the product—a one-time injection—after a three-month delay, which they took to give themselves some extra time to work on a risk evaluation… Read More »